A confirmatory study of masitinib in the treatment of Amyotrophic Lateral Sclerosis
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 30 Sep 2019 According to an AB science media release, the company expects to initiate this study in Q1 2020.
- 30 May 2019 According to an AB science media release, the design, optimization and timelines from this trial will be presented in the company webcast on 4 June 2019.
- 08 May 2018 New trial record